Introduction {#s1}
============

Total hip arthroplasty (THA) for patients with osteoarthritis is one of the most successful surgical interventions in general inducing substantial improvement of health-related quality of life of affected patients [@pone.0070359-Learmonth1]. Aseptic loosening is a typical long-term complication that significantly determines implant survival. Compared to regular bearings with conventional polyethylene, one advantage of metal-on-metal (MoM) bearings is that they produce less volumetric wear [@pone.0070359-Brockett1]. However, MoM hip replacements may release metallic products (i.e. particles, ions, metallo-organic compounds) due to wear and corrosion [@pone.0070359-Ishida1], [@pone.0070359-Yan1]. Metal ions from the corresponding alloying element (i.e. cobalt -- Co, chromium -- Cr, titanium -- Ti, nickel -- Ni, molybdenum -- Mo) can be measured in the joint itself as well as in surrounding tissue and body fluids, and may potentially cause local and or/systemic adverse reactions [@pone.0070359-Kwon1], [@pone.0070359-Langton1], [@pone.0070359-Langton2], [@pone.0070359-vanderStraeten1]. Recently, metal-related local adverse reactions (i.e. adverse reactions to metal debris, ARMD) in patients with MoM hip replacement gained substantial scientific and public attention [@pone.0070359-Bartens1], [@pone.0070359-Cohen1], [@pone.0070359-Godlee1], [@pone.0070359-Heneghan1], [@pone.0070359-Langton3], [@pone.0070359-Torjesen1]. Endoprothesis registries from Australia and the UK [@pone.0070359-AustralianOrthopaedic1], [@pone.0070359-AustralianOrthopaedic2], [@pone.0070359-NationalJoint1] indicated increased revision rates following hip replacements with MoM-bearing -- especially large-head THA and hip resurfacing arthroplasty (HRA). The risk of local adverse reactions of MoM-THA has been reported to correlate with the level of systemic metal ion concentrations [@pone.0070359-Kwon1], [@pone.0070359-Langton1], [@pone.0070359-vanderStraeten1], [@pone.0070359-Langton3], [@pone.0070359-Hart1], [@pone.0070359-Kwon2], [@pone.0070359-Matthies1]. However, several clinically relevant issues related to the safety of MoM-THA such as the impact of the different types of MoM implants on metal ion concentrations and related risks and the long-term course of postoperative metal ion concentrations require further investigation. Case reports [@pone.0070359-Machado1], [@pone.0070359-Oldenburg1] also suggest systemic risks due to metal burden after MoM-THA, but systematic research on this important issue is missing. There is substantial evidence from occupational medicine indicating that employees in metal producing and -processing plants exposured to chromium(VI) resp. cobalt compounds are at increased risk of nasal septum ulcerations, lung cancer resp. and cardiomyopathy [@pone.0070359-Linna1], [@pone.0070359-Schiele1], [@pone.0070359-Seidler1]. It has to be noted, however, that toxicity of Cr(III) compounds is substantially lower than those of Cr(VI) compounds. Because the primary route of metal exposure in occupational medicine is the respiratory tract, generalizability of these findings to patients with metallic hip replacement remains unclear.

Despite the current uncertainty a systematic review on the safety of MoM-hip replacements is missing. We systematically appraised published clinical and epidemiologic studies to clarify the following issues related to the safety of MoM-hip replacement:

-   What are median and maximum metal ion concentrations following MoM-hip replacement?

-   Which patient and implant related risk factors exist for elevated metal ion concentrations following MoM-hip replacement?

-   To what extent does the metal ion concentration after MoM-hip replacement predict local and systemic adverse reactions?

Methods {#s2}
=======

We undertook a systematic review to identify, summarize, and critically appraise the clinical and epidemiological evidence concerning the impact of metalliferous hip replacements on metal ion levels in body fluids. In addition to the type of bearing as the hypothesized determinant of metal ion concentrations we were particularly interested in patient characteristics as well as study quality characteristics as potential secondary determinants of metal ion concentrations after THR, and in the clinical consequences resulting from increased metal ion concentrations.

Inclusion criteria {#s2a}
------------------

All randomized controlled trials (RCTs) and epidemiological studies (cohort, case-control and cross-sectional studies, case series) with metal ion measurement (cobalt, chromium, titanium, nickel, molybdenum) in body fluids (full blood, serum, plasma, erythrocytes, synovia, urine) after implantation of metalliferous hip replacements in at least 20 patients were considered eligible. Studies were required to be published as an original article in English, German, or French language to be included.

Literature search {#s2b}
-----------------

Systematic electronic literature searches were conducted in PubMed and EMBASE (until January 19, 2012). Combinations of MeSH-terms were used to identify relevant trials with a high sensitivity. The exact search string used is provided in [table 1](#pone-0070359-t001){ref-type="table"}. Systematic electronic search was supplemented by hand search in the reference lists of the papers included, as well as all articles published in the „Journal of Bone and Joint Surgery British" between 2007 and 2011.Screening of titles and abstracts as well as full-text articles was done independently by two reviewers (F.H., A.H.). Disagreements were resolved by discussing within the whole team of reviewers.

10.1371/journal.pone.0070359.t001

###### Search string.

![](pone.0070359.t001){#pone-0070359-t001-1}

  \#                                                                                                                                                                                            Suchstring
  -------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **1**                                                                                                                                                            "Arthroplasty, Replacement, Hip"\[Mesh\] OR "Hip Prosthesis"\[Mesh\]
  **2**                                                                                        total hip arthroplast\*\[All Fields\] OR "THA"\[All Fields\] OR hip arthroplast\*\[All Fields\] OR total hip replacement\*\[All Fields\] OR hip replacement\*\[All Fields\] OR "hip prosthesis"\[All Fields\]
  **3**     "surface replacement"\[All Fields\] OR "hip resurfacing"\[All Fields\] OR hip resurfacing arthroplast\*\[All Fields\] OR "HRA"\[All Fields\] OR surface replacement arthroplast\*\[All Fields\] OR "articular surface replacement"\[All Fields\] OR "ASR"\[All Fields\] OR surface arthroplast\*\[All Fields\] OR "Birmingham Hip Resurfacing"\[All Fields\] OR "BHR"\[All Fields\]
  **4**                                                                                                                                                                                      \#1 OR \#2 OR \#3
  **5**                                                                                                                            "Chromium"\[Mesh\] OR "Chromium Alloys"\[Mesh\] OR "Cobalt"\[Mesh\] OR "Molybdenum"\[Mesh\] OR "Titanium"\[Mesh\] OR "Nickel"\[Mesh\]
  **6**                                                                               "Chromium"\[All Fields\] OR "Cr"\[All Fields\] OR Titanium\*\[All Fields\] OR "Ti"\[All Fields\] OR Nickel\*\[All Fields\] OR Cobalt\*\[All Fields\] OR "Co"\[All Fields\] OR Molybdenum\*\[All Fields\] OR „Mo"\[All Fields\]
  **7**                                                                                                                                                                                         \#5 OR \#6
  **8**                                                                                                                                                                   "Blood"\[Mesh\] OR "Urine"\[Mesh\] OR "Tissues"\[Mesh\]
  **9**                                                                                                                   "blood"\[All Fields\] OR "serum"\[All Fields\] OR "plasma"\[All Fields\] OR "urine"\[All Fields\] OR "tissue \[All Fields\] OR "tissues"\[All Fields\]
  **10**                                                                                                                                                                                        \#8 OR \#9
  **11**                                                                                                                                                                                   \#4 AND \#7 AND \#10
  **12**                                                                                                                                            \#11 NOT (letter\[pt\] OR editorial\[pt\] OR comment\[pt\] OR review\[pt\] OR meta-analysis\[pt\])
  **13**                                                                                                                                                                  \#12 NOT ((animals\[Mesh:NoExp\]) NOT (humans\[Mesh\]))
  **14**                                                                                                                                                 \#12 NOT ((animals\[Mesh:NoExp\]) NOT (humans\[Mesh\])) Limits: only items with abstracts

Data abstraction {#s2c}
----------------

The following information was abstracted from the studies included using standardized and beta tested evidence tables:

-   study characteristics (e.g. author, geographical region, study design, time points of assessment, follow-up period).

-   Patient characteristics (e.g. number of patients included and followed up to each point of assessment of metal ion level, UCLA -- University of California Los Angeles score [@pone.0070359-Zahiri1], body mass index).

-   Implant characteristics (type of bearing material and head size in three different groups of implants: small head (SH-)THA with head diameter ≤32 mm, stemmed large-head (LH-)THA with head diameter ≥36 mm, HRA).

-   Implant position (inclination of acetabular cup in the frontal plane).

-   Details on metal ion assessment, i.e. type of metal ions assessed (cobalt, chromium, titanium, nickel, molybdenum), the medium of assessment, method of analysis, metal ion levels (median, mean, interquartile range (IQR), outliers, definition of outliers.

-   Clinical results, i.e. local adverse reactions such as ARMD -- „adverse reactions to metal debris", systemic adverse reactions.

Rating of methodological study quality {#s2d}
--------------------------------------

Standardized study quality assessment was based on the CASP und SIGN Checklists [@pone.0070359-CASP1], [@pone.0070359-SIGN1]. Based on consented and a priori defined study quality criteria the risk of bias was rated for each study with the following categories:

-   very low risk of bias: „++"

-   low risk of bias: „+"

-   high risk of bias: „−"

We considered the following criteria to increase the risk of bias:

-   no consideration of confounding and/or explanatory factors such as other metallic implants, type, size, and position of implant.

-   missing information on the methods used to measure metal ion levels.

-   missing reference group without THR.

-   missing preoperative (baseline) metal ion assessment.

-   missing outcome data, i.e. loss to follow-up \>10% [@pone.0070359-Higgins1].

Evidence-synthesis {#s2e}
------------------

The qualitative evidence-synthesis included a comparison of the pre- vs. postoperative metal ion concentrations (median (alternatively: mean), IQR, maximum values) stratified by type of bearing as the primary explanatory factor. Patient characteristics (mean age, sex ratio) and implant characteristics (bearing size and position) were considered as secondary explanatory factors. Additionally, the definition of cut-off levels of metal ion concentrations in different studies was compared.

RCTs and epidemiological studies were analyzed separately. The detection limit of metal ions depends on the method and device used. The range of the detection limits reported and the handling of values below the detection rate was also part of the qualitative synthesis of the published evidence.

The course of metal ions in body fluids over time was assessed based on studies reporting baseline serum Co-values and at least 2 postoperative Co-measurements. In these studies, we investigated the course of median serum Co-concentration after implantation of hip replacements with different kinds of metal-on-metal bearings.

Metal ion concentrations in all tables and figures below generally relate to patients with unilateral THR, unless stated differently. We initially planned to conduct a quantitative summary (meta-analysis) of the results of qualitatively homogeneous studies with very low or low risk of bias.

Data on all relevant metal ions (cobalt, chromium, titanium, nickel, molybdenum) was extracted from the studies included. In the results section, we present cobalt levels as the proposed reference metal ion concentration after THR, as suggested by an international, multiprofessional expert panel [@pone.0070359-EFORT1].

Results {#s3}
=======

[Figure 1](#pone-0070359-g001){ref-type="fig"} summarizes the yield of systematic search and study selection [@pone.0070359-Moher1]. Overall, 104 studies (11 RCTs, 14 cohort studies, 1 case-control study, 55 cross-sectional studies, 23 case series) totaling 9.957 patients with measurement of metal ions in body fluids were identified and analyzed. The majority of studies were performed in Europe (n = 71) and North America (n = 26).

![Study flow chart of in- and excluded studies.\
[Figure 1](#pone-0070359-g001){ref-type="fig"} summarizes the yield of systematic search and study selection [@pone.0070359-Moher1]. Overall, 104 studies (11 RCTs, 14 cohort studies, 1 case-control study, 55 cross-sectional studies, 2 case series) were identified and analyzed.](pone.0070359.g001){#pone-0070359-g001}

Study characteristics RCTs {#s3a}
--------------------------

[Table 1](#pone-0070359-t001){ref-type="table"} summarizes the characteristics of the 11 RCTs included. RCTs were generally small and included between 13 and 117 patients. Two RCTs examined MoM vs. ceramic-polyethylene (CoP) [@pone.0070359-Brodner1], [@pone.0070359-Brodner2], five studies MoM vs. metal-polyethylene (MoP) [@pone.0070359-Dahlstrand1], [@pone.0070359-Engh1], [@pone.0070359-Hailer1], [@pone.0070359-MacDonald1], [@pone.0070359-Zijlstra1], [@pone.0070359-Zijlstra2], two studies examined MoM vs. ceramic-ceramic (CoC) [@pone.0070359-Zahiri1], [@pone.0070359-Grbl1], [@pone.0070359-Weissinger1], and two MoM vs. hip resurfacing arthroplasty (HRA) [@pone.0070359-Smolders1], [@pone.0070359-Vendittoli1], [@pone.0070359-Vendittoli2]. LH-THA was investigated in one US-American study [@pone.0070359-Engh1]. All other RCTs investigated MoM SH-THA.

Despite some methodological limitations such as missing description of patient recruitment/randomization, incomplete information on patient characteristics, and incomplete outcome data, all RCTs were considered as having low risk of bias ([Table 2](#pone-0070359-t002){ref-type="table"}).

10.1371/journal.pone.0070359.t002

###### Study characteristics of included randomized controlled trials (RCTs).

![](pone.0070359.t002){#pone-0070359-t002-2}

  Reference                                                                                                 Intervention   Bearing   Head size   Manufacturer                                                
  ---------------------- ----- ------------- -------- ---------------------------------------- ------- --- -------------- --------- ----------- -------------- --- --- --- -- --- --- --- --- --- --- -- --- ----
  Brodner 1997            RCT     Austria     27/55    59/60[\*](#nt107){ref-type="table-fn"}   66/69           100                      •                          •   •          •                          \+
  Brodner 2003            RCT     Austria     50/100   58/60[\*](#nt107){ref-type="table-fn"}   56/70   •       100                      •                          •   •          •           •   •      •   \+
  Dahlstrand 2009         RCT     Sweden        54                       65                      50     •       100                      •            •                 •          •                          \+
  Engh 2009               RCT       USA         91                                                              100                      •            •                        •       •           •          \+
  Grübl 2006              RCT     Austria     13/28                    67/62                    77/64   •       100                      •                      •       •          •           •   •      •   \+
  Hailer 2011             RCT     Sweden        85                                                      •       100                      •            •                 •          •                          \+
  MacDonald 2003          RCT     Canada        41                                                              100                      •            •                 •                      •              \+
  Smolders 2011b          RCT   Netherlands     71                                               41     •        46          54          •                              •          •       •              •   \+
  Vendittoli 2007+2010    RCT     Canada       117      50[\*](#nt107){ref-type="table-fn"}      36     •        45          55          •                              •          •               •      •   \+
  Weissinger 2011         RCT     Austria     42/80                      66                     67/68   •       100                      •                      •       •          •           •   •      •   \+
  Zijlstra 2009+2010      RCT   Netherlands     43                                                              100                      •            •                 •                      •              \+

Gathered information refer to patients with at least one metallic part of the bearing being investigated on metal ions.

Studies were summarized due to multiple reporting of identical patient population.

RCT: randomised controlled trial; comparison of 2 interventions, being different regarding e.g. bearing or type of implant; incl. metal ion measurement for all groups.1: Number of patients (with at least one metallic part of the bearing) being investigated on metal ions/total number of patients being investigated.

on metal ions.

2: Rounded mean age of patients with at least one metallic part of the bearing/rounded mean age of total number of patients being investigated.

on metal ions.

: Rounded weighted mean.

3: BMI  =  Body Mass Index.

4: THA  =  Total hip replacement.

5: HRA  =  Hip resurfacing arthroplasty.

MoM: Metal-on-Metal bearing.

MoP: Metal-on-Polyethylene bearing.

MoC: Metall-on-Ceramic bearing.

CoC: Ceramic-on-Ceramic bearing.

CoP: Ceramic-on-Polyethylene bearing.

6: Femoral head size 28--32 mm; small head.

7: Femoral head size ≥36 mm; large head.

incl. Protek, AlloPro, Sulzer Orthop., Centerpulse, Zimmer.

incl. Landander.

UCLA: Activity Score, University of California, Los Angeles.

Determination of metal ions in RCTs {#s3b}
-----------------------------------

[Table 3](#pone-0070359-t003){ref-type="table"} presents details of metal ion assessment in the RCTs included. All RCTs reported pre- and postoperative Co-concentrations. Nine [@pone.0070359-Brodner1], [@pone.0070359-Brodner2], [@pone.0070359-Dahlstrand1], [@pone.0070359-Engh1], [@pone.0070359-Hailer1], [@pone.0070359-Zijlstra1], [@pone.0070359-Zijlstra2], [@pone.0070359-Grbl1], [@pone.0070359-Weissinger1], [@pone.0070359-Vendittoli1], [@pone.0070359-Vendittoli2] RCTs preferred serum as medium for metal ion assessment. Long-term measurement ≥24 months were reported in five RCTs.[@pone.0070359-Brodner2], [@pone.0070359-Hailer1], [@pone.0070359-MacDonald1], [@pone.0070359-Zijlstra1], [@pone.0070359-Zijlstra2], [@pone.0070359-Weissinger1].

10.1371/journal.pone.0070359.t003

###### Points of time, investigated mediums, methods of analysis, and reporting of results of metal ion measurement in included RCTs.

![](pone.0070359.t003){#pone-0070359-t003-3}

  Reference               Metal ion measurement^1^   Metal ions   Medium   Technique   Outcome reported                                  
  ---------------------- -------------------------- ------------ -------- ----------- ------------------ --- --- --- --- --- --- --- --- ------------------------------
  Brodner 1997                       •                   •          •                                     •               •       •            mean, median, IQR
  Brodner 2003                       •                   •          •          •              •           •               •       •               median, IQR
  Dahlstrand 2009                    •                   •          •          •                          •   •           •           •        mean, median, IQR
  Engh 2009                          •                   •          •          •                          •   •       •   •   •       •           median, IQR
  Grübl 2006                         •                              •                                     •               •       •            median, IQR, range
  Hailer 2011                        •                                                        •           •   •           •           •               mean
  MacDonald 2003                     •                   •          •          •              •           •   •       •       •       •           median, IQR
  Smolders 2011b                     •                   •          •          •                          •   •   •                   •          median, range
  Vendittoli 2007+2010               •                   •          •          •                          •   •   •   •   •           •   mean, SD, range, median, IQR
  Weissinger 2011                    •                              •                         •           •               •       •            mean, median, IQR
  Zijlstra 2009+2010                 •                                         •              •           •   •           •       •              median, range

Studies were summarized due to multiple reporting of identical patient population.

2: Incl. all kinds of metal ion measurement in urin, e.g. 12- or 24 h urine.

3: AAS  =  All procedures of atomic absorption spectrometry.

4: ICP-MS  =  all procedures of inductively coupled plasma mass spectrometry.

n\. r.  =  Not reported.

SD: Standard deviation; SEM: Standard error of the mean; IQR: Interquartile range.Metal ion concentration in RCTs.

As detailed in [table 4](#pone-0070359-t004){ref-type="table"}, median Co-concentrations were elevated at each postoperative assessment after implantation of MoM SH-THA, MoM LH-THA, and HRA compared to THA with only one or without metallic part of the bearing. Following MoM SH-THA median serum Co-concentrations varied between 0.66--1.0 µg/L at 6 months [@pone.0070359-Brodner1], [@pone.0070359-Brodner2], [@pone.0070359-Dahlstrand1], [@pone.0070359-Engh1] and 0.73--1.2 µg/L at 2 years [@pone.0070359-Brodner2], [@pone.0070359-Dahlstrand1], [@pone.0070359-Engh1], [@pone.0070359-Weissinger1] after surgery. After MoM LH-THA median serum Co-levels of 0.66 µg/l and 0.73 µg/L were reported at 6-month and 2-year follow-up, respectively [@pone.0070359-Engh1]. After HRA, median whole blood Co-concentrations varied between 0.78 and 1.3 µg/L up six months und between 0.16 and 1.2 µg/L two years postoperatively [@pone.0070359-Smolders1], [@pone.0070359-Vendittoli1], [@pone.0070359-Vendittoli2]. The only direct comparison between MoM SH- and LH-THA revealed no relevant differences in the median serum Co-concentration [@pone.0070359-Engh1].

10.1371/journal.pone.0070359.t004

###### Concentrations of Co in µg/L for several interventions in RCTs.

![](pone.0070359.t004){#pone-0070359-t004-4}

                          Cobalt µg/L -- Comparison (Median; IQR; n)                                                                                                                                                                                                                                                                                                                                      
  ---------------------- -------------------------------------------- -------------- ------------------------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------- -------------------------------------------------------------- --------------------------------------------------------------
  Brodner 1997                            CoP SH-THA                      Serum                          0.15; 0.15--0.15; 28                                         0.15; 0.15--0.15; 28                                         0.15; 0.15--0.15; 28                                                                                                                                                   
  Brodner 2003                            CoP SH-THA                      Serum                          0.15; 0.15--0.15; 50                                         0.15; 0.15--0.15; 50                                         0.15; 0.15--0.15; 50                                          0.15; 0.15--0.15; 50                                           0.15; 0.15--0.15; 37                      
  Dahlstrand 2009                         MoP SH-THA                      Serum                           0.1; 0.05--0.25; 26                                          0.1; 0.05--0.2; 26                                           0.15; 0.06--0.3; 26                                           0.25; 0.1--0.4; 26                                                                                      
  Engh 2009                               MoP SH-THA                      Serum                          0.15; 0.10--0.22; 34                                         0.15; 0.11--0.20; 30                                         0.12; 0.10--0.17; 31                                          0.14; 0.09--0.19; 28                                                                                     
  Grübl 2006                              CoC SH-THA                      Serum                          0.15; 0.15--0.15; 15                                                                                   0.40; 0.15--0.70; 15[\*\*\*\*](#nt135){ref-type="table-fn"}                                                                                                                               
  Hailer 2011                             MoP SH-THA                      Serum               0.16; 44[\*\*](#nt133){ref-type="table-fn"}                                                                                                                                                                                                         0.24; 17[\*\*](#nt133){ref-type="table-fn"} ^2^         
  MacDonald 2003                          MoP SH-THA                   Erythrocytes                      0.11; 0.09--0.15; 18                                             not reported                                                 not readable                              0.17; 0.12--0.23; 18[3](#nt137){ref-type="table-fn"}                                                                     
  Smolders 2011b                          MoM SH-THA                   Whole blood     0.1; 0.1--0.6; 29[\*\*\*\*](#nt135){ref-type="table-fn"}     0.85; 0.1--4.0; 29[\*\*\*\*](#nt135){ref-type="table-fn"}    1.0; 0.1--4.2; 28[\*\*\*\*](#nt135){ref-type="table-fn"}      0.9; 0.1--2.7; 17[\*\*\*\*](#nt135){ref-type="table-fn"}                                                                   
  Vendittoli 2007+2010                    MoM SH-THA                   Whole blood     0.15; 0.06--0.42; 36[\*\*\*](#nt134){ref-type="table-fn"}    0.87; 0.25--3.57; 33[\*\*\*](#nt134){ref-type="table-fn"}    0.81; 0.23--2.10; 31[\*\*\*](#nt134){ref-type="table-fn"}     0.94; 0.24--4.89; 24[\*\*\*](#nt134){ref-type="table-fn"}                                                                  
  Weissinger 2011                         CoC SH-THA                      Serum                0.15; 38[\*](#nt132){ref-type="table-fn"}                                                                                               not reported                                 0.15; 0.15--0.4[4](#nt138){ref-type="table-fn"}                                                                       
  Zijlstra 2009+2010                      MoP SH-THA                      Serum       0.24; 0.18--0.65; 19[\*\*\*\*](#nt135){ref-type="table-fn"}                                                                                                                             0.18; 0.18--1.06; 19[\*\*\*\*](#nt135){ref-type="table-fn"}   0.30; 0.29--1.65; 14[\*\*\*\*](#nt135){ref-type="table-fn"}5   0.50; 0.40--1.30; 13[\*\*\*\*](#nt135){ref-type="table-fn"}6

                          Cobalt µg/L -- Intervention (Median; IQR; n)                                                                                                                                                                                                                                                                                                                                                                    
  ---------------------- ---------------------------------------------- -------------- ------------------------------------------------------------- ---------------------------------------------------------- ----------------------------------------------------------- -------------------------------------------------------------- ---------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------
  Brodner 1997                             MoM SH-THA                       Serum                          0.15; 0.15--0.15; 27                                          1.0; 0.35--1.35;27                                         1.1; 0.65--2.6; 27                                                                                                                                                                                    
  Brodner 2003                             MoM SH-THA                       Serum                          0.15; 0.15--0.15; 50                                          1.0; 0.5--1.4; 50                                           1.0; 0.6--2.2; 50                                           0.75; 0.4--2.85; 50                                                              0.9; 0.4--1.7;36                                        
  Dahlstrand 2009                          MoM SH-THA                       Serum                           0.05; 0.05--0.1; 28                                         0.75; 0.5--1.05; 28                                         0.8; 0.5--1.05; 28                                           0.85; 0.65--1.3; 28                                                                                                                      
  Engh 2009                                MoM SH-THA                       Serum                          0.16; 0.09--0.29; 24                                         0.72; 0.49--0.98; 21                                       0.72; 0.48--1.02; 22                                          0.77; 0.48--1.19; 21                                                                                                                     
                                           MoM LH-THA                       Serum                          0.14; 0.08--0.22; 31                                         0.66; 0.37--0.85; 29                                       0.70; 0.49--1.10; 26                                          0.73; 0.47--1.99; 26                                                                                                                     
  Grübl 2006                               MoM SH-THA                       Serum                          0.15; 0.15--0.15; 13                                                                                  1.4; 0.5--10.5; 13[\*\*\*\*](#nt135){ref-type="table-fn"}                                                                                                                                                                
  Hailer 2011                              MoM SH-THA                       Serum               0.09; 41[\*\*](#nt133){ref-type="table-fn"}                                                                                                                                                                                                                       0.86; 19[\*\*](#nt133){ref-type="table-fn"} ^2^                         
  MacDonald 2003                           MoM SH-THA                    Erythrocytes                      0.14; 0.09--0.17; 23                                             not reported                                               not readable                                             1.10; 0.66--2.43; 223                                                                                                                     
  Smolders 2011b                              HRA                        Whole blood     0.1; 0.1--0.8; 33[\*\*\*\*](#nt135){ref-type="table-fn"}     1.3; 0.1--23; 33[\*\*\*\*](#nt135){ref-type="table-fn"}    1.25; 0.6--8.3; 33[\*\*\*\*](#nt135){ref-type="table-fn"}     1.2; 0.5--22; 16[\*\*\*\*](#nt135){ref-type="table-fn"}                                                                                                    
  Vendittoli 2007+2010                        HRA                        Whole blood     0.16; 0.06--1.05; 44[\*\*\*](#nt134){ref-type="table-fn"}    0.78; 0.25--1.61 51[\*\*\*](#nt134){ref-type="table-fn"}   0.67; 0.23--2.09; 57[\*\*\*](#nt134){ref-type="table-fn"}    0.16; 0.20--2.89; 48[\*\*\*](#nt134){ref-type="table-fn"}                                                                                                   
  Weissinger 2011                          MoM SH-THA                       Serum                0.15; 42[\*](#nt132){ref-type="table-fn"}                                                                                             not reported                                                 1.2; 0.8--2.74                                                                                                                        
  Zijlstra 2009+2010                       MoM SH-THA                       Serum       0.18; 0.18--1.77; 24[\*\*\*\*](#nt135){ref-type="table-fn"}                                                                                                                          0.77; 0.18--15.57; 24[\*\*\*\*](#nt135){ref-type="table-fn"}   0.88; 0.29--7.02; 19[\*\*\*\*](#nt135){ref-type="table-fn"} [5](#nt139){ref-type="table-fn"}   1.10; 0.50--11.0; 17[\*\*\*\*](#nt135){ref-type="table-fn"} [6](#nt140){ref-type="table-fn"}

THA  =  Total hip arthroplasty; HRA  =  Hip resurfacing arthroplasty.

SH  =  Small head; LH  =  Large head; IQR  =  Interquartil range.

Hint:.

Values of the given studies were reported, if they fitted to the fixeds timeframes; if several measurements fitted to one timeframe, those values were reported.

being nearest to the timeframes given above; e. g. values were reported 3 months and 5 months postoperative \> values 5 months postoperatively are shown in this table.

Median, n.

Mean, n.

Mean, range, n.

Median, range, n.

metal ion measurement mean 6.8 years postoperatively.

metal ion measurement mean 3.2 years postoperatively.

metal ion measurement median 24.3 months postoperatively.

metal ion measurement mean 67 months postoperatively.

metal ion measurement mean 121 months postoperatively.

Two RCTs directly compared MoM SH-THA vs. HRA and revealed qualitatively different results: While Smolders et al. [@pone.0070359-Smolders1] observed higher median and maximum Co-concentrations following HRA compared to MoM SH-THA, Vendittoli et al.[@pone.0070359-Vendittoli1], [@pone.0070359-Vendittoli2] did not observe relevant differences in mean Co-concentrations following HRA and MoM SH-THA. THA with only one metallic part of the bearing resulted in not or only slightly elevated serum Co-concentrations ([Table 4](#pone-0070359-t004){ref-type="table"}).

Study characteristics epidemiological studies {#s3c}
---------------------------------------------

[Table 5](#pone-0070359-t005){ref-type="table"} summarizes aggregated characteristics of the epidemiological studies included. [Table 6](#pone-0070359-t006){ref-type="table"} provides details of the characteristics of each epidemiological study included. Metal ion concentrations following HRA were reported in 48 studies (52%). Information on inclination and anteversion were reported in 30 studies (32%) and in 16 (17%) studies, respectively. Information on mean age was reported in 66 studies (71%). The sex distribution of patients was reported in 64 studies (69%) and varied substantially with 19 to 90% of the study populations being female.

10.1371/journal.pone.0070359.t005

###### Summary of study characteristics of included epidemiological studies.
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  ------------------------------------- ------------------------------------------------------------------------------- ----------------
  **[Study design]{.ul}**                                                Cohort study                                        N = 14
                                                                      Case-control study                                     N = 1
                                                                     Cross-sectional study                                   n = 55
                                                                          Case series                                        n = 23
  **[Geographical region]{.ul}**                                            Europe                                           n = 63
                                                                         North America                                       n = 23
                                                                             Asia                                            n = 6
                                                                           Australia                                         n = 1
  **[Patients characteristics]{.ul}**                             number of patients (range)                                20--789
                                                                   mean age (n = 70 studies)                                 37--70
                                                             distribution of sex (n = 68 studies)                        19--90% female
                                                **BMI** [\*](#nt141){ref-type="table-fn"} **(n = 29 studies)**          
                                         **mean** [\*\*](#nt142){ref-type="table-fn"} (range of means, n = 25 studies)     22.8--28.5
                                                           range of extreme values (n = 11 studies)                         17--56.6
                                                         **median** (range of medians, n = 9 studies)                        26--28
                                                            range of extreme values (n = 6 studies)                          19--42
  ------------------------------------- ------------------------------------------------------------------------------- ----------------

  [Implant characteristics]{.ul}                                
  -------------------------------- ---------------------------- ------------
  **Intervention**                           **THA**             **n = 70**
                                            MoM LH-THA             n = 26
                                            MoM SH-THA             n = 42
                                               MoP                 n = 17
                                               MoC                 n = 1
                                               CoC                 n = 4
                                               CoP                 n = 2
                                             **HRA**             **n = 47**
  **Manufacturer**                            Zimmer               n = 56
                                              DePuy                n = 26
                                           Smith&Nephew            n = 34
                                           Corin Group             n = 12
                                    Wright Medical Technology      n = 12
                                              others               n = 27
                                           not reported            n = 3
  **[Study quality]{.ul}**          ++ (very low risk of bias)     n = 0
                                      \+ (low risk of bias)        n = 7
                                      \- (high risk of bias)       n = 86

Including both sexes and different points of measurement (e.g. preoperative, or at follow up).

Including weighted means for several study cohorts.

10.1371/journal.pone.0070359.t006

###### Study characteristics of included epidemiological studies.
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  Reference                  Study design   Geographical region   Number of patients^1^                                Age (mean)^2^                                Proportion women (%)   BMI^3^   Intervention    Bearing     Head size   Manufacturer   Inclination   Anteversion   UCLA Activity Score   Study quality                                                   
  ------------------------- -------------- --------------------- ----------------------- ------------------------------------------------------------------------- ---------------------- -------- -------------- ------------ ----------- -------------- ------------- ------------- --------------------- --------------- --- --- -------- --- --- --- --- --- --- --- --- ----
  Antoniou 2008                   CO              Canada                   174                              58[\*](#nt153){ref-type="table-fn"}                              43                          60            40           •            •                                                                               •     •      •                           •   −
  Beaulé 2011                     CO              Canada                   52                               57[\*](#nt153){ref-type="table-fn"}                              25              •           50            50           •                                                                                        •                            •       •       •   \+
  Bernstein 2011a                 CO              Canada                   104                                              61                                               48                         100                         •                                                                                            •     •      •                   •   •   •   \+
  Boyer 2009                      CO              France                   109                                              54                                               49                         100                         •                                                                              •                   •                      •   •           \+
  De Souza 2010                   CO           Great Britain               56                                               52                                               45                                       100           •                                                                                                                 •                       \+
  Garbuz 2010                     CO              Canada                 26/104                         n\. r./52[\*](#nt153){ref-type="table-fn"}                                           •           50            50           •                                                                                        •         •                                  •   −
  Isaac 2009a                     CO           Great Britain               60                                               54                                               65                         100                         •                           •                                                  •                          •                   •   •       \+
  Jacobs 1998                     CO                USA                    55                               61[\*](#nt153){ref-type="table-fn"}                              53                         100                                      •                                                                 •                   •      •                               \+
  Lavigne 2011                    CO              Canada                   137                              54[\*](#nt153){ref-type="table-fn"}                              38              •          100                         •                                                                                        •         •      •   •           •   •       •   −
  Lazennec 2009                   CO              France                   109                                              54                                               49              •          100                         •                                                                              •                   •                      •   •   •       −
  Pattyn 2011                     CO              Belgium                 52/70           51[\*](#nt153){ref-type="table-fn"}/52[\*](#nt153){ref-type="table-fn"}            35              •           40            60           •                                         •                                    •                   •          •       •   •           •   \+
  Smolders 2011a                  CO            Netherlands                92                                                                                                39              •           35            65           •                                                                              •                   •                  •                   −
  Sunderman 1989                  CO                USA                    32                                                                                                                           100                                      •                                                              n\. r.       •                        •               −      
  Witzleb 2006                    CO              Germany                  185                                                                                               49              •           40            60           •                                                                              •                   •          •                           −
  Hart 2011a                      CC           Great Britain               176                                                                                               50                        n\. r.        n\. r.         •                                                                                        •         •      •   •   •       •               −
  Bernstein 2011b                 CS              Canada                   34                                               60                                               50                          59            41           •                                                                                            •     •      •                   •   •   •   −
  Bisseling 2011                  CS            Netherlands                57                                                                                                40              •           63            37           •                                                                              •                   •                  •                   −
  Bolland 2011                    CS           Great Britain               185                                              58                                               60                         100                         •                                                                                        •         •          •           •   •   •       −
  Braun 1986                      CS              France                   24                                                                                                                           100                         •                                                                                        •                                                −
  Brodner 2004                    CS              Austria                  60                                               62                                               55              •          100                         •                                                                           n\. r.       •                            •       •   −      
  Campbell 2010                   CS                USA                    519                                                                                                                                        100           •                                                                                                n\. r.               −                  
  Clarke 2003                     CS                USA                    44                                               57                                                                           50            50           •                                                                              •                              •   •       •               −
  Damie 2004                      CS              France                   48                                               70                                               38                         100                                      •                                                                 •                   •      •                               −
  Daniel 2006                     CS           Great Britain               135                              54[\*](#nt153){ref-type="table-fn"}                                                          38            62           •                                                                              •                   •          •                           −
  Daniel 2008                     CS           Great Britain               56                               60[\*](#nt153){ref-type="table-fn"}                                                         100                         •                                                                                            •     •          •                           −
  Daniel 2010                     CS           Great Britain               426                                              55                                                                           10            90           •                                                                                            •     •          •   •                       −
  Davda 2011                      CS           Great Britain               92                                               60                                               67                          10            90           •                                                                           n\. r.           •     •      •       •   •           −      
  De Haan 2008                    CS              Belgium                  214                                              51                                               42                                       100           •                                                                                                  •      •   •       •       •       •   −
  De Smet 2008                    CS              Belgium                  26                                               53                                               73                          23            77           •                                                                                            •     •      •   •           •               −
  Gleizes 1999                    CS              France                   41                                               54                                               51                         100                         •                                                                              •                   •                      •               −
  Hallows 2011                    CS                USA                    46                               57[\*](#nt153){ref-type="table-fn"}                              54                         100                         •            •                                                                               •                            •   •   •   •   −
  Hart 2006                       CS           Great Britain               68                               59[\*](#nt153){ref-type="table-fn"}                              43                          50            50           •            •                                                              n\. r.       •   •     •              •               −      
  Hart 2008                       CS           Great Britain               26                                               53                                               42              •                        100           •                                                                                                             •               •           −
  Hart 2009a                      CS           Great Britain               26                                               52                                               65                                       100           •                                                                                                n\. r.   •   •       −                  
  Hart 2009b                      CS           Great Britain             139/164                                                                                             34              •           35            65           •            •                            •                                              •                    •           •               −
  Jacobs 1991                     CS                USA                    42                               59[\*](#nt153){ref-type="table-fn"}                              45                         100                         •            •                                                              n\. r.       •                                        −      
  Karamat 2005                    CS              Austria                 50/75                                                                                              46                         100                         •            •                            •                                    •                   •                                      −
  Khan 2008                       CS           Great Britain               21                                               54                                               38                                       100           •                                                                                                             •   •           •           −
  Kwon 2010                       CS           Great Britain               70                               55[\*](#nt153){ref-type="table-fn"}                              56                                       100           •                                                                                                             •       •   •               −
  Kwon 2011                       CS                USA                    178                                              56                                               34                          11            89           •            •                                                                 •                   •          •       •   •   •           −
  Langton 2008+2009               CS           Great Britain               160                              53[\*](#nt153){ref-type="table-fn"}                              40              •                        100           •                                                                                                         •   •               •   •   •   −
  Langton 2010                    CS           Great Britain               247                                                                                                                           8             92           •                                                                                        •                •   •               •   •   •   −
  Langton 2011a                   CS           Great Britain               789                                                                                                                                        100           •                                                                                                         •   •       •       •   •   •   −
  Langton 2011b                   CS           Great Britain               723                              53[\*](#nt153){ref-type="table-fn"}                              38                                       100           •                                                                                                         •   •       •       •   •   •   −
  Langton 2011c                   CS           Great Britain               257                                                                                                                           20            80           •                                                                                        •                •                   •   •   •   −
  Lhotka 2003                     CS              Austria                  259                              55[\*](#nt153){ref-type="table-fn"}                              65                         100                         •                                                                           n\. r.       •         •                              −      
  Maclean 2010                    CS           Great Britain               30                                                                                                                                         100           •                                                                                                n\. r.               −                  
  Maezawa 2002                    CS               Japan                   75                               67[\*](#nt153){ref-type="table-fn"}                              84                         100                         •            •                                                              n\. r.       •                        •               −      
  Matthies 2011a                  CS           Great Britain               120                              57[\*](#nt153){ref-type="table-fn"}                              67                          50            50           •                                                                                        •         •      •   •   •       •   •   •       −
  Matthies 2011b                  CS           Great Britain               105                                                                                               72                          34            66           •                                                                                        •         •      •   •   •       •   •   •       −
  Migaud 2011                     CS              France                  30/62                           40/40[\*](#nt153){ref-type="table-fn"}                             17              •          100                         •                                                           •                  •                   •                      •               −
  Milosev 2005                    CS             Slovenia                  43                               56[\*](#nt153){ref-type="table-fn"}                              72              •          100                         •                                                                              •                   •                      •               −
  Moroni 2008                     CS               Italy                   46                               48[\*](#nt153){ref-type="table-fn"}                              52                          57            43           •                                                                              •                   •          •                           −
  Moroni 2011                     CS               Italy                   95                               54[\*](#nt153){ref-type="table-fn"}                              48              •           63            37           •                                                                              •                   •          •               •           −
  Pazzaglia 1983                  CS               Italy                   20                                               69                                                                          100                                      •                                                              n\. r.                                •               −      
  Pelt 2011                       CS                USA                    39                               56[\*](#nt153){ref-type="table-fn"}                              44                         100                         •                                                                                        •                                •   •   •   •   −
  Pilger 2002                     CS              Austria                 46/53                          58[\*](#nt153){ref-type="table-fn"}/n. r.                           54                         100                         •                                                                           n\. r.                 •                              −      
  Rasquinha 2006                  CS                USA                   30/40           58[\*](#nt153){ref-type="table-fn"}/58[\*](#nt153){ref-type="table-fn"}                                       100                         •            •                                              •                  •                   •                      •               −
  Saito 2006                      CS               Japan                  50/90                          55[\*](#nt153){ref-type="table-fn"}/n. r.                           90                         100                         •            •                                                                 •                   •                              •       −
  Sarmiento-González 2008         CS               Spain                   22                                                                                                46                         100                                      •                                                              n\. r.                                •               −      
  Savarino 2002                   CS               Italy                   41                               54[\*](#nt153){ref-type="table-fn"}                              63                         100                         •            •                                                                 •                   •                                      −
  Savarino 2003                   CS               Italy                   41                               49[\*](#nt153){ref-type="table-fn"}                              59                         100                         •                                                                              •                   •                                      −
  Savarino 2006                   CS               Italy                  42/65                           57/59[\*](#nt153){ref-type="table-fn"}                             45                         100                         •                                         •                                    •                   •                      •               −
  Schaffer 1999                   CS              Austria                  76                               58[\*](#nt153){ref-type="table-fn"}                              61                         100                         •                                                                           n\. r.                 •                              −      
  Tkaczyk 2010                    CS              Canada                   127                              55[\*](#nt153){ref-type="table-fn"}                              63                         100                         •                                                                              •                   •                                  •   −
  Triclot 2009                    CS              France                  30/39                                                                                                              •          100                         •                                                                              •                   •                                      −
  Underwood 2011                  CS           Great Britain               130                              56[\*](#nt153){ref-type="table-fn"}                              65                                       100           •                                                                                                         •   •               •   •       −
  Walter 2008                     CS             Australia                 29                                                                                                                                         100           •                                                                                                             •                           −
  Williams 2011                   CS              Canada                   75                                                                                                                •           73            27           •            •                                                                               •     •                          •       •   −
  Akihiko 2011                    CA               Japan                   20                                               51                                                                          100                         •                                                                              •                   •                                      −
  Allan 2007                      CA                USA                    35                                               51                                               43              •                        100           •                                                                                                                 •                       −
  Castelli 2011                   CA               Italy                   53                                                                                                                           100                         •                                                                                        •                •                               −
  Corradi 2011                    CA           Great Britain               31                                               62                                               23              •                        100           •                                                                                                                 •                       −
  Daniel 2007a+2009               CA           Great Britain               26                                               53                                                               •                        100           •                                                                                                             •               •       •   −
  Daniel 2007b                    CA           Great Britain               262                                              56                                               28                      n\. r.^\$^    n\. r.^\$^       •                                                                                            •     •          •   •                       −
  Delaunay 2000                   CA              France                   58                                               60                                               36              •          100                         •                                                                              •                   •                                      −
  Delaunay 2004                   CA              France                   89                                               60                                               37                         100                         •                                                                              •                   •                              •       −
  Desy 2011                       CA              Canada                   91                                               53                                               19                                       100           •                                                                                                         •                   •   •   •   −
  Girard 2011                     CA              France                   22                                               44                                               73              •          100                         •                                                                              •                   •                          •           −
  Grübl 2007                      CA              Austria                 22/98                                          n\. r./56                                                           •          100                         •                                                                              •                   •                                  •   −
  Hart 2011b                      CA           Great Britain               100                                                                                               51              •                        100           •                                                                                                  •      •   •   •       •   •   •       −
  Imanishi 2010                   CA               Japan                   33                                               60                                               88              •          100                         •                                                                                        •                •                   •           −
  Isaac 2009b                     CA           Great Britain               77                                                                                                27                                       100           •                                                                                                         •                               −
  Kim 2011                        CA              Canada                   97                                               48                                               22              •                        100           •                                                                                                                     •       •   •   •   −
  Ladon 2004                      CA           Great Britain               95                                                                                                                           100                         •                                                                              •                   •                                      −
  Maezawa 2004                    CA               Japan                   44                                               63                                               80              •          100                         •                                                                              •                   •                                      −
  Marker 2008                     CA              Austria                 70/98                                          n\. r./56                                                                      100                         •                                                                              •                   •                                      \-
  Masse 2003                      CA               Italy                   30                                               52                                               67                         100                         •                                                                                            •     •                                      −
  Nikolaou 2011                   CA              Canada                   166                                              50                                               46                         100                         •                                                                                            •     •      •                   •   •   •   −
  Skipor 2002                     CA                USA                    25                                               49                                               32                                       100           •                                                                                                                     •                   −
  Vendittoli 2011                 CA              Canada                   29                                               50                                               48              •          100                         •                                                                                        •         •                          •       •   −
  Yang 2011                       CA               China                   25                                               37                                                               •                        100           •                                                                                                                     •                   −

Gathered information refer to patients with at least one metallic part of the bearing being investigated on metal ions.

Studies were summarized due to multiple reporting of identical patient population.

Study design:.

CO: Cohort study, examination on metal ions at 2 or more points of time, reference group being different regarding state of surgery, implant type, bearing.

or the like is necessary; incl. metal ion measurement for all groups.

CC: Case-control study, cases with elevated metal ion concentrations, controls with not elevated metal ions concentrations, retrospective detection of exposition (bearing, implant typ); incl. metal ion measurement for all groups.

CS: Cross-sectional study, examination on metal ions at one point of time, reference group being different regarding state of surgery, implant type, bearing or the like is necessary; incl. metal ion measurement for all groups.

CA: Case series, examination of 2 or more persons on metal ions, at one or more points of time; incl. metal ion measurement.

1: Number of patients (with minimum one metallic part of the bearing) being examined on metal ions/total number of patients being examined on metal ions.

2: Rounded mean age of patients with minimum one metallic part of the bearing/rounded mean age of total group of examined patients.

: Rounded weighted mean.

3: BMI  =  Body Mass Index.

4: THA  =  Total hip arthoplasty.

5: HRA  =  Hip resurfacing arthroplasty.

MoM: Metal-Metal bearing.

MoP: Metal-Polyethylene bearing.

MoC: Metall-Ceramic bearing.

CoC: Ceramik-Ceramik bearing.

CoP: Ceramik-Polyethylene bearing.

n\. r.: Not reported.

6: Femorale head size 28--32 mm; small head.

7: Femorale head size ≥36 mm; large head.

Incl. Protek, AlloPro, Sulzer Orthop., Centerpulse, Zimmer.

Incl. Landander.

Incl. Midland med. Technologies, Medizintechnik Wien, Endo Plus.

UCLA: University of California, Los Angeles.

\$ distribution was not reported for the whole group.

The vast majority of studies (n = 86; 83%) had significant methodological shortcomings such as a lack of reference group, lack of preoperative baseline assessment, lack of essential information on implant characteristics or metal ion measurement, and/or insufficient follow-up rates and were therefore considered as having a high risk of bias.

Determination of metal ions in epidemiological studies {#s3d}
------------------------------------------------------

87 and 85 epidemiological studies reported Co and Cr values following hip replacement, respectively. No study differentiated between Cr(III) and Cr(VI). Metal ion concentration was most often measured in whole blood (n = 51), serum (n = 47), and urine (n = 19). Few studies investigated ion levels in erythrocytes (n = 2), plasma (n = 5), or in synovia (n = 3). Inductively coupled plasma mass spectrometry (ICP-MS) was used in 56 studies (60%), atomic absorption spectrometry (AAS) in 33 studies (36%), and inductively coupled plasma atomic emission spectrometry (ICP-AES) resp. inductively coupled plasma optical emission spectrometry (ICP-OES) in three studies for metal ion detection. Only 24studies (26%) reported preoperative (baseline) metal ion concentrations. For more details on metal ion assessment in the epidemiological studies included please refer to [table 7](#pone-0070359-t007){ref-type="table"}.

10.1371/journal.pone.0070359.t007

###### Points of time, investigated mediums, methods of analysis, and reporting of results of metal ion measurement in included epidemiological studies.
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  Reference                  Metal ion measurement^1^   Metal ions   Medium   Technique   Outcome reported                                                                              
  ------------------------- -------------------------- ------------ -------- ----------- ------------------ --- --- -------- -------- -------------------- --- -------- --------------- ------------------------------
  Antoniou 2008                                             •          •                                     •   •     •                                                       •                 median, IQR
  Beaulé 2011                           •                   •          •          •                          •   •                             •                               •           mean, range, median, IQR
  Bernstein 2011a                                           •          •                                     •   •     •                                                       •                 median, IQR
  Boyer 2009                            •                   •          •          •              •                                             •                                                 median, IQR
  De Souza 2010                         •                   •          •          •              •           •   •                             •                  •            •                     mean
  Garbuz 2010                           •                   •          •          •                          •   •                             •                               •                 median, IQR
  Isaac 2009a                           •                   •          •                         •           •   •     •                                                       •                    median
  Jacobs 1998                           •                              •                         •           •   •                             •            •     •                              mean, range
  Lavigne 2011                          •                   •          •          •                          •   •     •                                                       •             mean, range, median
  Lazennec 2009                         •                   •          •          •              •           •   •                             •                  •                              median, IQR
  Pattyn 2011                           •                   •          •          •                          •   •     •                                                       •         mean, range, SD, median, IQR
  Smolders 2011a                        •                   •          •          •                          •   •     •                       •                               •              median, range, IQR
  Sunderman 1989                        •                   •          •          •              •           •   •                             •            •     •                            mean, SEM, range
  Witzleb 2006                                              •          •          •                          •   •                             •                  •                              median, IQR
  Hart 2011a                                                                                     •           •   •     •                                                       •                median, range
  Bernstein 2011b                                                                 •                          •   •     •                                                       •                 median, IQR
  Bisseling 2011                        •                              •                                     •   •     •                       •                               •                median, range
  Bolland 2011                                                                                   •           •   •     •                                                       •                median, range
  Braun 1986                                                                      •              •           •   •                                          •     •                              mean, range
  Brodner 2004                                                                                   •           •   •                             •                  •                                 median
  Campbell 2010                       n\. r.                •          •                                     •       n\. r.   n\. r.                                                    
  Clarke 2003                                                                     •                          •   •                             •                               •              median, SEM, range
  Damie 2004                                                                                     •           •   •     •                                                       •                    n\. r.
  Daniel 2006                                                          •          •              •           •   •     •                                    •                  •                     mean
  Daniel 2008                                                          •          •              •           •   •     •                                    •   n\. r.       mean       
  Daniel 2010                         n\. r.                •                                                    •              •         median, IQR                                   
  Davda 2011                                                                                     •           •   •     •                                                       •           mean, range, median, IQR
  De Haan 2008                                                                                   •           •   •                             •                               •               mean, range, IQR
  De Smet 2008                                                                                   •           •   •                             •                               •              median, range, IQR
  Gleizes 1999                                                                    •                          •                                 •                  •                            mean, SD, range
  Hallows 2011                                                                                   •           •   •                             •                               •                median, range
  Hart 2006                                                                       •              •           •   •     •                                                       •                     mean
  Hart 2008                                                                                      •           •   •     •                                                       •                   mean, SD
  Hart 2009a                          n\. r.                •          •          •                                             •      median, range, IQR                               
  Hart 2009b                                                                                     •           •   •     •                                                       •                 median, IQR
  Jacobs 1991                                                                                    •                                             •            •     •                              mean, range
  Karamat 2005                                                                                   •           •   •     •                                                       •                median, range
  Khan 2008                                                                                      •           •                                                                 •               mean, range, SD
  Kwon 2010                                                                                      •           •   •                             •                               •              median, range, IQR
  Kwon 2011                                                                                      •           •   •                             •                               •              median, range, IQR
  Langton 2008+2009                                                                              •           •   •     •                       •                               •           mean, range, median, IQR
  Langton 2010                                                                                   •           •   •     •                       •                               •           mean, range, median, IQR
  Langton 2011a                                                                                  •           •   •     •                       •                               •              median, range, IQR
  Langton 2011b                                                                                  •           •   •                             •                               •                    median
  Langton 2011c                                                                                  •           •         •                       •                n\. r.      median      
  Lhotka 2003                                               •          •                         •           •   •     •                                          •                               mean, SEM
  Maclean 2010                                                                    •                          •   •     •                                    •   n\. r.      n\. r.      
  Maezawa 2002                                                         •                         •           •   •                             •            •     •                              mean, range
  Matthies 2011a                                                                                 •           •   •     •                                        n\. r.   median, range  
  Matthies 2011b                                                                                 •           •   •     •                                                       •             mean, median, range
  Migaud 2011                                                                                    •           •   •     •                                                       •               mean, SD, range
  Milosev 2005                          •                   •          •          •              •           •   •                             •                  •                      mean, SD, range, median, IQR
  Moroni 2008                                                                     •              •           •   •                             •                  •                        mean, SEM, median, range
  Moroni 2011                                                                     •              •           •   •                             •                  •                        mean, SD, range, median
  Pazzaglia 1983                                                                                 •               •     •                                    •     •                                mean, SD
  Pelt 2011                                                                                      •           •   •                             •                               •              median, IQR, range
  Pilger 2002                                                          •          •              •           •   •     •                                    •     •                             median, range
  Rasquinha 2006                                                                                 •           •   •                             •                  •                        mean, SD, range, median
  Saito 2006                                                                                     •               •                             •                  •                            mean, SD, range
  Sarmiento-González 2008                                                         •              •           •   •     •                                    •                  •                mean, SEM, IQR
  Savarino 2002                                                                   •              •           •   •                             •                  •                        mean, SEM, median, range
  Savarino 2003                                                                                  •           •   •                             •                  •                        mean, SEM, median, range
  Savarino 2006                                                                                  •           •   •                             •                  •                        mean, SEM, median, range
  Schaffer 1999                                                        •          •              •           •   •     •                                    •     •                           median, range, IQR
  Tkaczyk 2010                                              •          •          •              •           •   •     •                                                       •                 median, IQR
  Triclot 2009                                                                                   •           •   •     •                                          •            •                     mean
  Underwood 2011                                                                                 •           •   •     •                                                       •                 mean, range
  Walter 2008                                               •          •          •              •           •   •     •        •              •                  •            •                 mean, median
  Williams 2011                                                                   •              •           •   •                             •                               •              median, SD, range
  Akihiko 2011                                                         •          •              •               •                             •                  •                        mean, range, median, IQR
  Allan 2007                            •                   •          •          •              •           •   •                             •                               •               mean, SD, median
  Castelli 2011                         •                   •          •          •              •           •   •     •                                                       •                    median
  Corradi 2011                                                                                   •           •   •     •                                    •                  •              median, range, IQR
  Daniel 2007a+2009                     •                   •          •          •              •           •   •     •                                    •                  •           mean, range, median, IQR
  Daniel 2007b                                              •          •          •              •           •   •     •                       •                               •                     mean
  Delaunay 2000                                                                                  •           •         •                                          •                                 n\. r.
  Delaunay 2004                                                        •                         •           •         •                                          •                                  mean
  Desy 2011                                                                                      •           •   •     •                                                       •                    median
  Girard 2011                                                                                    •           •   •     •                                                       •             mean, range, median
  Grübl 2007                                                                                     •           •   •                             •                  •                             median, range
  Hart 2011b                                                                                     •           •   •     •                                                       •              median, range, IQR
  Imanishi 2010                         •                   •          •                                     •   •                             •                  •            •                 median, IQR
  Isaac 2009b                           •                   •          •          •                          •   •     •                                                       •                    median
  Kim 2011                              •                   •          •          •                          •   •              •              •            •                  •         mean, SD, range, median, IQR
  Ladon 2004                            •                   •          •          •                          •   •     •                                                       •                    median
  Maezawa 2004                                              •          •          •              •               •                             •                  •                            mean, SD, range
  Marker 2008                                                                                    •           •   •                             •                  •                             median, range
  Masse 2003                            •                   •                                                •   •     •                                    •     •                            mean, SD, median
  Nikolaou 2011                         •                              •          •              •           •   •     •                                                       •                 median, IQR
  Skipor 2002                           •                   •          •                                     •   •                             •            •     •                                  mean
  Vendittoli 2011                       •                   •          •                                     •   •     •                                                       •         mean, SD, range, median, IQR
  Yang 2011                             •                   •          •          •                          •   •                             •            •     •                            mean, SD, range

Studies were summarized due to multiple reporting of identical patient population.

2: Incl. all kinds of metal ion measurement in urin, e.g. 12- or 24 h urine.

3: AAS  =  All procedures of atomic absorption spectrometry.

4: ICP-MS  =  all procedures of inductively coupled plasma mass spectrometry.

n\. r.  =  Not reported.

SD: Standard deviation; SEM: Standard error of the mean; IQR: Interquartile range.

Metal ion concentrations in epidemiological studies {#s3e}
---------------------------------------------------

[Table 8](#pone-0070359-t008){ref-type="table"} summarizes median serum Co-concentrations, 75th percentiles, and maximum values of Co-concentrations before and after hip replacement stratified by the type of intervention (MoM SH-THA, MoM LH-THA, HRA). After MoM SH-THA median Co-concentrations varied between 0.65 and 1.5 µg/L at six months and between 0.7 and 1.7 µg/L two years postoperatively [@pone.0070359-Smolders1], [@pone.0070359-Clarke1], [@pone.0070359-Witzleb1]. After HRA, median serum Co-concentrations varied between 1.12 and 3.7 µg/L six months and between 0.54 and 4.28 µg/L two years postoperatively indicating higher Co-levels after HRA vs. MoM SH-THA [@pone.0070359-Clarke1], [@pone.0070359-Witzleb1], [@pone.0070359-Allan1], [@pone.0070359-Beaule1], [@pone.0070359-Garbuz1], [@pone.0070359-Smolders2]. Median Co-concentrations after MoM LH-THA varied between 0.7 and 3.26 µg/L six months and between 3.77 and 5.38 µg/L two years postoperatively [@pone.0070359-Beaule1], [@pone.0070359-Garbuz1], [@pone.0070359-Imanishi1].

10.1371/journal.pone.0070359.t008

###### Median serum Co concentration in µg/L before and after hip replacement in epidemiological studies.
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  [Serum Cobalt-values (µg/L) pre- vs. postoperative]{.ul}                                                           
  ---------------------------------------------------------- --------- --------------- -------------- -------------- ----------------
  **range of medians**                                        **0.1**   **0.65--1.5**   **0.8--1.4**   **0.7--1.7**   **0.26--1.55**
  number of studies                                              1            2              3              3               10
  **range of 75th percentile**                                             **1,7**      **0.9--2,5**                     **1.8**
  number of studies                                                           1              2                              1
  **range of maximum values**                                 **1.3**      **4.1**        **1.9**        **1.4**      **0.92--50.1**
  number of studies                                              1            1              2              2               9

  [MoM LH-THA]{.ul}                                                                               
  ------------------------------ --------------- --------------- --------------- ---------------- ---------------
  **range of medians**            **0.09--0.3**   **0.7--3.26**   **1.1--5.09**   **3.77--5.38**   **0.7--4.5**
  number of studies                     3               2               3               2                5
  **range of 75th percentile**    **0.2 --0.3**      **0.9**      **1.65--7.5**      **7.2**         **1.15**
  number of studies                     2               1               2               1                1
  **range of maximum values**       **0.57**        **10.25**       **12.85**        **9.59**      **5.6--79.3**
  number of studies                     1               1               1               1                4

  [HRA]{.ul}                                                                                         
  ------------------------------ ---------------- ---------------- ---------------- ---------------- ----------------
  **range of medians**            **0.08--0.28**   **1.12--3.7**    **0.51--4.31**   **0.54--4.28**   **0.83--2.82**
  number of studies                     4                4                6                6                10
  **range of 75th percentile**       **0.2**          **4,5**         **0.7--6**        **0.7**      
  number of studies                     1                1                3                1                .
  **range of maximum values**     **0.19--2.6**    **5.09--11.4**   **7.42--11.4**   **7.13--17.6**   **8.96--228**
  number of studies                     3                2                3                4                7

One important result of our systematic review is that the maximum serum Co-levels were consistently higher at all postoperative assessments in patients who received MoM LH-THA [@pone.0070359-Langton3], [@pone.0070359-Beaule1], [@pone.0070359-Garbuz1], [@pone.0070359-Imanishi1], [@pone.0070359-Hallows1], [@pone.0070359-Langton4], [@pone.0070359-Pelt1], [@pone.0070359-Williams1] and HRA [@pone.0070359-Langton1], [@pone.0070359-Langton2], [@pone.0070359-Langton3], [@pone.0070359-Clarke1], [@pone.0070359-Witzleb1], [@pone.0070359-Allan1], [@pone.0070359-Beaule1], [@pone.0070359-Garbuz1], [@pone.0070359-Smolders2], [@pone.0070359-Langton4], [@pone.0070359-Williams1], [@pone.0070359-Bisseling1], [@pone.0070359-Langton5], [@pone.0070359-Langton6], [@pone.0070359-Moroni1], [@pone.0070359-Moroni2] compared to patients who received MoM SH-THA [@pone.0070359-Clarke1], [@pone.0070359-Witzleb1], [@pone.0070359-Smolders2], [@pone.0070359-Hallows1], [@pone.0070359-Bisseling1], [@pone.0070359-Moroni1], [@pone.0070359-Moroni2], [@pone.0070359-Grbl2], [@pone.0070359-Marker1], [@pone.0070359-Milosev1], [@pone.0070359-Rasquinha1], [@pone.0070359-Savarino1], [@pone.0070359-Savarino2], [@pone.0070359-Savarino3] ([Table 8](#pone-0070359-t008){ref-type="table"}).

[Tables 9](#pone-0070359-t009){ref-type="table"} and [10](#pone-0070359-t010){ref-type="table"} summarize the results of comparative epidemiological studies. In accordance with these indirect comparisons from epidemiological studies, median Co-concentrations following MoM LH-THA and HRA tended to be higher compared to MoM SH-THA. Consistently, MoM LH-THA, MoM SH-THA, and HRA resulted in higher metal ion concentrations than THA with CoP, CoC, and MoP-implants.

10.1371/journal.pone.0070359.t009

###### Co concentration in µg/L in serum/whole blood for MoM LH-THA or HRA vs. MoM SH-THA in epidemiological studies.
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                    Cobalt µg/L - Intervention (Median; IQR; n)                                                                                                                                                                                                                                                 
  ---------------- --------------------------------------------- ------------- ------------------------------------------------------ ------------------------------------------------------- ------------------------------------------------------- --------------------------------------------------------- -------------------------------------------------------------
  Antoniou 2008                     MoM LH-THA                    Whole blood                                                                1.8; 58[\*](#nt179){ref-type="table-fn"}                2.3; 58[\*](#nt179){ref-type="table-fn"}                                                                   
                                        HRA                       Whole blood                                                                2.3; 70[\*](#nt179){ref-type="table-fn"}                2.4; 70[\*](#nt179){ref-type="table-fn"}                                                                   
  Pattyn 2011                          HRA_1                      Whole blood        0.45; 22[\*](#nt179){ref-type="table-fn"}               1.1; 22[\*](#nt179){ref-type="table-fn"}                           0.95; 0.73--1.2; 22                                       0.8; 0.6--0.9; 21                     
                                       HRA_2                      Whole blood        0.45; 20[\*](#nt179){ref-type="table-fn"}               1.55; 20[\*](#nt179){ref-type="table-fn"}                           1.7; 1.1--2.4; 18                                        1.6; 1.2--2.1; 18                     
  Smolders 2011a                        HRA                          Serum      0.1; 0.1--2.6; 60[\*\*](#nt180){ref-type="table-fn"}   1.2; 0.1--11.4; 51[\*\*](#nt180){ref-type="table-fn"}   1.3; 0.1--11.4; 42[\*\*](#nt180){ref-type="table-fn"}    1.5; 0.7--17.6; 21[\*\*](#nt180){ref-type="table-fn"}   
  Witzleb 2006                          HRA                          Serum                                                                   2.2; 56[\*](#nt179){ref-type="table-fn"}                3.1; 50[\*](#nt179){ref-type="table-fn"}                 4.3; 23[\*](#nt179){ref-type="table-fn"}          
  Bisseling 2011                        HRA                          Serum                          not reported                                                                               1.1; 0.1--7.7; 36[\*\*](#nt180){ref-type="table-fn"}                                                             
  Clarke 2003                           HRA                          Serum                                                                                                                                                                                    2.2; 22[\*](#nt179){ref-type="table-fn"}          
  Hallows 2011                      MoM LH-THA                       Serum                                                                                                                                                                                                                                       0.7; 0.0--14.0; 10[\*\*](#nt180){ref-type="table-fn"} ^^2^^
  Moroni 2011                          HRA_1                         Serum                                                                                                                                                                             0.55; 0.08--8.96; 15[\*\*](#nt180){ref-type="table-fn"}  
                                       HRA_2                         Serum                                                                                                                                                                                                                                       0.72; 0.3--5.6; 20[\*\*](#nt180){ref-type="table-fn"} ^^3^^
  Daniel 2006                           HRA                       Whole blood                                                                                                                      1.3; 26[\*\*\*](#nt181){ref-type="table-fn"}                                                                 
  Daniel 2008                       MoM LH-THA                    Whole blood                                                                                                                      2.3; 28[\*\*\*](#nt181){ref-type="table-fn"}                                                                 
  Garbuz 2010                       MoM LH-THA                       Serum                       0.11; 0.1--0.2; 13                                                                                             5.09; 3.0--7.5; 13                                       5.38; 3.5--7.2; 13                     

                    Cobalt µg/L -- Comparison (Median; IQR; n)                                                                                                                                                                                                                                                
  ---------------- -------------------------------------------- ------------- ------------------------------------------------------ ------------------------------------------------------- ------------------------------------------------------ --------------------------------------------------------- -------------------------------------------------------------
  Antoniou 2008                     MoM SH-THA                   Whole blood                                                                2.5; 28[\*](#nt179){ref-type="table-fn"}                2.6; 28[\*](#nt179){ref-type="table-fn"}                                                                  
                                                                                                                                                                                                                                                                                                              
  Pattyn 2011                       MoM SH-THA                   Whole blood        0.45; 10[\*](#nt179){ref-type="table-fn"}               1.4; 10[\*](#nt179){ref-type="table-fn"}                            1.7; 0.7--2.2; 9                                         1.35; 0.9--2; 8                      
                                                                                                                                                                                                                                                                                                              
  Smolders 2011a                    MoM SH-THA                      Serum      0.1; 0.1--1.3; 32[\*\*](#nt180){ref-type="table-fn"}   0.65; 0.1--4.1; 30[\*\*](#nt180){ref-type="table-fn"}   0.8; 0.1--1.9; 23[\*\*](#nt180){ref-type="table-fn"}     0.7; 0.1--1.4; 8[\*\*](#nt180){ref-type="table-fn"}    
  Witzleb 2006                      MoM SH-THA                      Serum                                                                   1.5; 18[\*](#nt179){ref-type="table-fn"}                1.4; 13[\*](#nt179){ref-type="table-fn"}                1.7; 34[\*](#nt179){ref-type="table-fn"}          
  Bisseling 2011                    MoM SH-THA                      Serum                          not reported                                                                               0.8; 0.1--1.9; 21[\*\*](#nt180){ref-type="table-fn"}                                                            
  Clarke 2003                       MoM SH-THA                      Serum                                                                                                                                                                                   1.3; 22[\*](#nt179){ref-type="table-fn"}          
  Hallows 2011                      MoM SH-THA                      Serum                                                                                                                                                                                                                                       1.0; 0.3--14.0;10[\*\*](#nt180){ref-type="table-fn"} ^2^
  Moroni 2011                      MoM SH-THA_1                     Serum                                                                                                                                                                            0.98; 0.34--5.32; 25[\*\*](#nt180){ref-type="table-fn"}  
                                   MoM SH-THA_2                     Serum                                                                                                                                                                                                                                      0.86; 0.08--7.31; 35[\*\*](#nt180){ref-type="table-fn"} ^3^
  Daniel 2006                       MoM SH-THA                   Whole blood                                                                                                                      1.7; 20[\*\*\*](#nt181){ref-type="table-fn"}                                                                
  Daniel 2008                       MoM SH-THA                   Whole blood                                                                                                                      1.7; 20[\*\*\*](#nt181){ref-type="table-fn"}                                                                
  Garbuz 2010                          HRA                          Serum                       0.13; 0.1--0.2; 13                                                                                             0.51; 0.4--0.7; 13                                      0.54; 0.4--0.7; 13                     

Values of the given studies were reported, if they fitted to the fixeds timeframes; if several measurements fitted to one timeframe, those values.

were reported being nearest to the timeframes given above; e. g. values were reported 3 months and 5 months postoperative \> values 5 months.

postoperatively are shown in this table.

Median; n.

Median; range; n.

Mean; n.

^2^ metal ion measurement at mean 73 months postoperatively.

^3^ metal ion measurement mean 5 years postoperatively.

10.1371/journal.pone.0070359.t010

###### Co concentration in serum/whole blood for MoM SH-THA, MoM LH-THA or HRA vs. MoP, CoP, CoC, MoC THA in epidemiological studies.
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                    Cobalt µg/L -- Intervention (Median; IQ-Range; n)                                                                                                                                                                                                              
  ---------------- --------------------------------------------------- ------------- ------------------------------------------- ------------------------------------------- ------------------------------------------- --------------------------------------------------------- ------------------------------------------------------------------------------------------
  Antoniou 2008                            HRA                          Whole blood                                               2.3; 70[\*](#nt184){ref-type="table-fn"}    2.4; 70[\*](#nt184){ref-type="table-fn"}                                                             
                                       MoM LH-THA                       Whole blood                                               1.8; 58[\*](#nt184){ref-type="table-fn"}    2.3; 58[\*](#nt184){ref-type="table-fn"}                                                             
                                       MoM SH-THA                       Whole blood                                               2.5; 28[\*](#nt184){ref-type="table-fn"}    2.6; 28[\*](#nt184){ref-type="table-fn"}                                                             
  Hart 2006                                HRA                          Whole blood                                                                                                                                            4.18; 34[\*\*\*](#nt186){ref-type="table-fn"}       
                                                                                                                                                                                                                                                                                   
  Karamat 2005                         MoM SH-THA                       Whole blood                                                                                                                                       0.69: 0.19--3.7; 25[\*\*](#nt185){ref-type="table-fn"}   
  Savarino 2002                        MoM SH-THA                          Serum                                                                                                                                          0.97; 0.34--5.32; 26[\*\*](#nt185){ref-type="table-fn"}  
  Hallows 2011                         MoM SH-THA                          Serum                                                                                                                                                                                                     1.0; 0.3--14.0;10[\*\*](#nt185){ref-type="table-fn"} [4](#nt189){ref-type="table-fn"}
                                       MoM LH-THA                          Serum                                                                                                                                                                                                     0.7; 0.0--14.0; 10[\*\*](#nt185){ref-type="table-fn"} [4](#nt189){ref-type="table-fn"}
  Rasquinha 2006                       MoM SH-THA                          Serum                                                                                                                                                                                                    1.55; 0.58--7.93; 10[\*\*](#nt185){ref-type="table-fn"} [4](#nt189){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                   
  Pattyn 2011                             HRA_1                         Whole blood   0.45; 22[\*](#nt184){ref-type="table-fn"}   1.1; 22[\*](#nt184){ref-type="table-fn"}               0.95; 0.73--1.2; 22                                 0.8; 0.6--0.9; 21                     
                                          HRA_2                         Whole blood   0.45; 20[\*](#nt184){ref-type="table-fn"}   1.55; 20[\*](#nt184){ref-type="table-fn"}               1.7; 1.1--2.4; 18                                  1.6; 1.2--2.1; 18                     
                                       MoM SH-THA                       Whole blood   0.45; 10[\*](#nt184){ref-type="table-fn"}   1.4; 10[\*](#nt184){ref-type="table-fn"}                1.7; 0.7--2.2; 9                                    1.35; 0.9--2; 8                      
  Hart 2009b                               HRA                          Whole blood                                                                                                                                                                                                                                   1.71; 1.29--2.33; 88
  Isaac 2009                           MoM SH-THA                       Whole blood   0.45; 19[\*](#nt184){ref-type="table-fn"}   0.51; 19[\*](#nt184){ref-type="table-fn"}   0.83; 19[\*](#nt184){ref-type="table-fn"}        1.0; 19[\*](#nt184){ref-type="table-fn"} ^2^        

                    Cobalt µg/L -- Comparison (Median; IQ-Range; n)                                                                                                                                                                                                              
  ---------------- ------------------------------------------------- ------------- ------------------------------------------- ------------------------------------------ -------------------------------------------- --------------------------------------------------------- ------------------------------------------------------------------------------------------
  Antoniou 2008                         MoP THA                       Whole blood                                               1.8; 18[\*](#nt184){ref-type="table-fn"}    1.7; 18[\*](#nt184){ref-type="table-fn"}                                                             
                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                 
  Hart 2006                             MoP THA                       Whole blood                                                                                                                                                                                                                    2.48; 34[\*\*\*](#nt186){ref-type="table-fn"} ^3^
                                                                                                                                                                                                                                                                                 
  Karamat 2005                        MoP SH-THA                      Whole blood                                                                                                                                       0.19: 0.19--1.07; 25[\*\*](#nt185){ref-type="table-fn"}  
  Savarino 2002                       MoP SH-THA                         Serum                                                                                                                                          0.62; 0.19--1.45; 15[\*\*](#nt185){ref-type="table-fn"}  
  Hallows 2011                       MoP SH/LH-THA                       Serum                                                                                                                                                                                                                   0.35; 0.1--0.9; 10[\*\*](#nt185){ref-type="table-fn"} ^3^
                                                                                                                                                                                                                                                                                 
  Rasquinha 2006                      MoP SH-THA                         Serum                                                                                                                                                                                                    0.26; 0.15--3.91; 10[\*\*](#nt185){ref-type="table-fn"} [4](#nt189){ref-type="table-fn"}
                                      CoP SH-THA                         Serum                                                                                                                                                                                                    0.15; 0.15--0.40; 10[\*\*](#nt185){ref-type="table-fn"} [4](#nt189){ref-type="table-fn"}
  Pattyn 2011                        CoC SH-THA_1                     Whole blood    0.6; 8[\*](#nt184){ref-type="table-fn"}    0.5; 8[\*](#nt184){ref-type="table-fn"}     0.5; 8[\*](#nt184){ref-type="table-fn"}            0.45; 8[\*](#nt184){ref-type="table-fn"}          
                                     CoC SH-THA_2                     Whole blood   0.5; 10[\*](#nt184){ref-type="table-fn"}    0.5; 10[\*](#nt184){ref-type="table-fn"}    0.5; 10[\*](#nt184){ref-type="table-fn"}           0.5; 10[\*](#nt184){ref-type="table-fn"}          
                                                                                                                                                                                                                                                                                 
  Hart 2009b                            CoC THA                       Whole blood                                                                                                                                                        0.21; 0.17--0.25; 25                    
  Isaac 2009                          MoC SH-THA                      Whole blood   0.55; 22[\*](#nt184){ref-type="table-fn"}   0.5; 22[\*](#nt184){ref-type="table-fn"}   0.72; 22 [\*](#nt184){ref-type="table-fn"}        0.9; 22[\*](#nt184){ref-type="table-fn"} ^2^        

Median; n.

Median; range; n.

Mean; n.

^2^ metal ion measurement at 34 months postoperatively.

^3^ metal ion measurement at 5 years postoperatively.

metal ion measurement at 36 months postoperatively.

Conclusions on the role of patient characteristics (age, sex) on metal ion concentration could not be drawn due to a lack of standardization in the design and reporting of the epidemiological studies included.

The levels of Cr and other metal ions showed similar distributions and lead to the same conclusions as the Co-ion levels reported (data available on request from the corresponding author).

Course of metal ion concentration pre- vs. postoperative {#s3f}
--------------------------------------------------------

[Figure 2](#pone-0070359-g002){ref-type="fig"} provides an overview of the course of metal ion concentrations in studies reporting baseline serum Co-values and at least 2 postoperative Co-measurements. All MoM-interventions showed an increase in median serum Co-concentration. Again, highest median levels were observed in patients with HRA or MoM LH-THA. In some studies median Co-concentrations peaked at 12 months follow-up and declined thereafter. Other studies showed stable (increased) median serum Co-concentrations until 4-years follow-up.

![Course of median serum Co-concentration after implantation of hip replacements with different kinds of metal-on-metal bearings.\
[Figure 2](#pone-0070359-g002){ref-type="fig"} provides an overview of the course of metal ion concentrations in studies reporting baseline serum Co-values and at least 2 postoperative Co-measurements. All MoM-interventions showed an increase in median serum Co-concentration. Again, highest median levels were observed in patients with HRA or MoM LH-THA. In some studies median Co-concentrations peaked at 12 months follow-up and declined thereafter. Other studies showed stable (increased) median serum Co-concentrations until 4-years follow-up.](pone.0070359.g002){#pone-0070359-g002}

Maximum Co-concentrations in epidemiological studies {#s3g}
----------------------------------------------------

Authors applied different definitions of outlier/extreme values of Co-concentration ranging between 0.25 and 124.9 µg/L for all bearings. Details on the reported maximum Co-concentrations in epidemiological studies are provided in [table 11](#pone-0070359-t011){ref-type="table"}. MoP THA generally resulted in lower extreme values than MoM hip replacements. In studies investigating MoM SH-THA maximum Co-concentrations ranged between 0.72 and 26.0 µg/L. The highest Co-concentrations were observed after MoM LH THA (range of maximum values: 1.8--79.3 µg/L) and after HRA (range of maximum values: 1.4--124.9).

10.1371/journal.pone.0070359.t011

###### Maximal postoperative Co-concentrations after THA in RCTs and epidemiological studies.
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  Reference                         Intervention                                                                 Outlier
  ------------------------ ------------------------------- -------------------------------------------------------------------------------------------------------------------
  **Brodner 2003**                  not reported                          overall postoperative: 2 outlier with Co-concentrations in serum of 24 and 119.2 µg/L
  **Brodner 2004**                     MoM THA                             overall postoperative: 3 outlier with Co-concentrations in serum of 4.9--12.9 µg/L
  **Dahlstrand 2009**                MoM SH-THA                              overall postoperative: 7 outlier with Co-concentrations in serum up to \>9 µg/L
                                       MoP THA                           overall postoperative: 9 outlier with Co-concentrations in serum up to approx. 1.3 µg/L
  **Engh 2009**                      MoM LH-THA                   overall postoperative: 2 outlier with Co-concentrations in serum of approx. 1.8 and approx. 3.4 µg/L
                                     MoM SH-THA                   overall postoperative: 2 outlier with Co-concentrations in serum of approx. 2.0 and approx. 2.8 µg/L
                                       MoP THA                    overall postoperative: 8 outlier with Co-concentrations in serum of approx. 0.25-- approx. 2.75 µg/L
  **Zijlstra 2009+2010**             MoM SH-THA                           2 years postoperative: 2 outlier with Co-concentrations in serum of 7.0 and 15.6 µg/L
                                    not reported                               5 years postoperative: 1 outlier with Co-concentration in serum of 7.0 µg/L
                                    not reported                              10 years postoperative: 1 outlier with Co-concentrations in serum of 11 µg/L
  **Allan 2007**                         HRA                                                outlier: 1.5-fold boxwidth above 75th percentile
                                                                             overall postoperative: 6 outlier Co-concentrations in serum of 13.6--124.9 µg/L
  **Antoniou 2008**                  MoM SH-THA                  overall postoperative: 5 outlier with Co-concentrations in whole blood of approx. 4-- approx. 6.5 µg/L
                                     MoM LH-THA                  overall postoperative: 9 outlier with Co-concentrations in whole blood of approx. 2.5-- approx. 10 µg/L
                                         HRA                overall postoperative: approx. 11 outlier with Co-concentrations in whole blood of approx. 3.3--approx. 11.7 µg/L
  **Bernstein 2011a**                MoM SH-THA                  overall postoperative: 6 outlier with Co-concentrations in whole blood of approx. 2.5-- approx. 19 µg/L
                                     MoM LH-THA                overall postoperative: 3 outlier with Co-concentrations in whole blood of approx. 24.0-- approx. 37.5 µg/L
  **Bernstein 2011b**       MoM SH-THA + MoM LH-THA + HRA                    whole cohort consists of oulier with Co-concentrations in whole blood ≥10 µg/L
  **Daniel 2010**                                                                        outlier: values above upper quartile + 3-fold IQ-range
                                    not reported                  overall postoperative: 14 outlier with Co-concentrations in plasma of approx. 8.8-- approx. 14.5 µg/L
  **De Haan 2008**                   HRA (steep)                    overall postoperative: 9 outlier with Co-concentrations in serum of approx. 10-- approx. 112 µg/L
                                   HRA (non-steep)              overall postoperative: approx. 12 outlier with Co-concentrations in serum of approx. 5-- approx. 30 µg/L
  **Delauanay 2000**                 MoM SH-THA                             overall postoperative: 6 patients with Co-concentrations in whole blood \>5 µg/L
  **Delaunay 2004**                  MoM SH-THA                                       laboratory reference value value 5 µg/L for Co in whole blood
                                                                   overall postoperative: 15 outlier with Co-concentrations in whole blood \>5 µg/L with max. 36 µg/L

  Reference                            Intervention                                                                     Outlier
  ------------------- ----------------------------------------------- ------------------------------------------------------------------------------------------------------------
  **De Smet 2008**                   MoM (unilateral)                              overall postoperative: 1 outlier with Co-concentration in serum of approx. 93 µg/L
                                      MoM (bilateral)                              overall postoperative: 1 outlier with Co-concentration in serum of apptox. 62 µg/L
  **Garbuz 2010**                           HRA                                 overall postoperative: 2 outlier with Co-concentrations in serum of approx. 1.5+1.8 µg/L
                                        MoM LH-THA                                overall postoperative: 1 outlier with Co-concentrations in serum of approx. 2.4 µg/L
  **Grübl 2007**                        MoM SH-THA                                overall postoperative: 2 outlier with Co-concentrations in serum 8.4 resp. 50.1 µg/L
  **Hallows 2011**                      MoM SH-THA                                    overall postoperative: 1 outlier with Co-concentration in serum of 14.0 µg/L
                                        MoM LH-THA                                 overall postoperative: 1 outlier with Co-concentration in whole blood of 79.3 µg/L
  **Imanishi 2010**                     MoM LH-THA                          overall postoperative: 5 outlier with Co-concentrations in serum approx. 2.2-- approx. 4.6 µg/L
  **Isaac 2009a**                 MoM SH-THA + CoC SH-THA                        overall postoperative: 8 outlier with Co or Cr-concentrations in whole blood \> 0 µg/L
  **Isaac 2009b**                           HRA                                     overall postoperative: 6 outlier with Co-concentrations in whole blood \>10 µg/L
  **Kim 2011**                              HRA                         overall postoperative: approx. 14 outlier with Co-concentrations in serum approx. 3.0-- approx. 49 µg/L
  **Kwon 2010**                    HRA (no pseudotumor)                     overall postoperative: 3 outlier with Co-concentrations in serum approx. 7.0-- approx. 9.5 µg/L
  **Kwon 2011**                           MoP THA                                     overall postoperative: 1 outlier with Co-concentrations in serum of 3.8 µg/L
                                   HRA (no pseudotumor)                     overall postoperative: 4 outlier with Co-concentrations in serum approx. 6.0-- approx. 10.5 µg/L
  **Langton 2011a**                   HRA (incl. ASR)                     overall postoperative: several outlier with Co-concentrations in serum of approx. 20 µg/L--240 µg/L
  **Langton 2011b**                 HRA -- DePuy (ASR)                             overall postoperative: 56 outlier (23 %) with Co-concentrations in serum \>7 µg/L
                       HRA -- Smith&Nephew/Wright Medical Technology                overall postoperative: 29 outlier (6 %) with Co-concentrations in serum \>7 µg/L
  **Langton 2011c**       HRA -- DePuy (ASR); MoM LH-THA -- DePuy              overall postoperative: 67 outlier (26,1 %) with Co- or Cr-concentrations in serum \>7 µg/L
                          HRA -- DePuy (ASR); MoM LH-THA -- DePuy             overall postoperative: 30 outlier (11,7 %) with Co- or Cr-concentrations in serum \>20 µg/L
  **Lavigne 2011**                 MoM LH-THA -- Zimmer                overall postoperative: 2 outlier with Co-concentrations in whole blood of approx. 6.3 and approx. 6.8 µg/L
                                   MoM LH-THA -- Biomet                overall postoperative: 14 outlier with Co-concentrations in whole blood of approx. 1.5-- approx. 13.0 µg/L
                                    MoM LH-THA -- DePuy                 overall postoperative: 9 outlier with Co-concentrations in whole blood of approx. 2.2--approx. 8.4 µg/L
                                MoM LH-THA -- Smith&Nephew              overall postoperative: 5 outlier with Co-concentrations in whole blood of approx. 3.0-- approx. 5.2 µg/L
  **Lazennec 2009**                     MoM SH-THA                                 overall postoperative: 1 outlier with highest Co-concentration in serum of 47 µg/L

  Reference                        Intervention                                                               Outlier
  -------------------------- ------------------------- ----------------------------------------------------------------------------------------------------------------------
  **MacDonald 2003**                MoM SH-THA               overall postoperative: 3 outlier with Co-concentrations in erythrocytes of approx. 7.0-- approx. 26.0 µg/L
                                      MoP THA                        overall postoperative: 1 outlier with Co-concentration in erythrocytes of approx. 3.0 µg/L
  **Marker 2008**                   MoM SH-THA                          overall postoperative: 2 outlier with Co-concentrations in serum 50.1 and 60.6 µg/L
  **Matthies 2011b**               not reported               more than half of the patients with pseudotumors with Co- or Cr-concentrations in whole blood \> 7 µg/L
  **Nikolaou 2011**           MoM LH-THA + MoM SH-THA          overall postoperative: 10 outlier with Co-concentrations in whole blood approx. 3.0-- approx. 5.5 µg/L
  **Pattyn 2011**              MoM SH-THA -- Zimmer                  overall postoperative: 2 outlier with Co-concentrations in whole blood of approx. 5.2 µg/L
                                   HRA -- Zimmer             overall postoperative: 2 outlier with Co-concentrations in whole blood of approx. 1.4 and approx. 3.4 µg/L
                                HRA -- Smith&Nephew           overall postoperative: 3 outlier with Co-concentrations in whole blood of approx. 4.0-- approx. 6.7 µg/L
  **Pelt 2011**                     MoM LH-THA            overall postoperative: 4 outlier (unilateral) with Co-concentrations in serum of approx. 1.2-- approx. 5.6 µg/L
                                    MoM LH-THA          overall postoperative: 2 excluded outlier with Co-concentrations in serum of 5.6 (bilateral) +79.3 (unilateral) µg/L
  **Pilger 2002**                     MoM THA                            overall postoperative: 16 outlier with Co-concentration in whole blood of \>5 µg/L
  **Savarino 2002**                                                                 reference value for Co of 0.72 µg/L (Italian health agency)
                                    MoM SH-THA                      overall postoperative: 17 outlier (65 %) with Co-concentrations in serum \> reference value
                                      MoP THA                          overall postoperative: 90% with Co-concentrations in serum \> reference limit 0.4 µg/L
  **Savarino 2003**                 MoM SH-THA            overall postoperative: 24 outlier with Co-concentrations in serum \> median reference value of 0,29 µg/L for Co
  **Savarino 2006**                 MoM SH-THA             overall postoperative: 5 outlier (33 %) with Co-concentrations in serum \> reference value of 0.4 µg/L for Co
  **Schaffer 1999**                   MoM THA                    overall postoperative: 12 outlier with Co-concentration in whole blood of \>5-- approx. 33.5 µg/L
  **Smolders 2011b**                MoM SH-THA                overall postoperative: 5 outlier with Co-concentration in whole blood of approx. 2.1-- approx. 4.2 µg/L
                                        HRA                       overall postoperative: 10 outlier with Co-concentration in whole blood of approx. 3.0--22.8 µg/L
  **Tkaczyk 2010**                  MoM SH-THA               overall postoperative: 12 outlier with Co-concentrations in whole blood of approx. 4.0-- approx. 8.2 µg/L
  **Vendittoli 2007+2010**                                           outlier: 1.5--3 boxwidth above 3. quartile; extreme values: \>3 boxwidth above 3. quartile
                                    MoM SH-THA                overall postoperative: 5 outlier with Co-concentration in whole blood of approx. 2.5-- approx. 5.7 µg/L
                                        HRA                   overall postoperative: 9 outlier with Co-concentration in whole blood of approx. 3.0-- approx. 6.5 µg/L
  **Vendittoli 2011**               MoM LH-THA                 overall postoperative: 2 outlier with Co-concentrations in whole blood approx. 5.8-- approx. 7.0 µg/L
  **Williams 2011**                 MoM LH-THA                                overall postoperative: 1 outlier with Co-concentration in serum \>50µg/L
                                        HRA                        overall postoperative: 2 outlier with Co-concentrations in serum of approx. 3.0 and \>50 µg/L;
  **Witzleb 2006**                  MoM SH-THA                    overall postoperative: 4 outlier with Co-Concentrations in serum approx. 5.5-- approx. 9.5 µg/L
                                        HRA                        overall postoperative: 4 outlier with Co-Concentrations in serum approx. 6.5-- approx. 23 µg/L

Due to substantial differences in the design, interventions, methods of metal ion assessment, study populations and study reporting, we considered statistical meta-analysis not to be indicated.

Local clinical reactions {#s3h}
------------------------

Local metal-related adverse reactions were reported in 9 epidemiological studies [@pone.0070359-Kwon1], [@pone.0070359-Langton1], [@pone.0070359-Langton3], [@pone.0070359-Kwon2], [@pone.0070359-Matthies1], [@pone.0070359-Langton4], [@pone.0070359-Williams1], [@pone.0070359-Bolland1], [@pone.0070359-DeSmet1]. As summarized in [table 12](#pone-0070359-t012){ref-type="table"} ARMD, metallosis and pseudotumors were the most frequently reported metal-related adverse reactions. Six studies reported Co-concentrations in well and poorly functioning implants [@pone.0070359-Kwon1], [@pone.0070359-Hart1], [@pone.0070359-Kwon2], [@pone.0070359-Matthies1], [@pone.0070359-Langton4]. Cases with local metal-related adverse reactions (poorly functioning implants) had consistently higher metal ion concentrations than patients with well-functioning THA ([Figure 3](#pone-0070359-g003){ref-type="fig"}).

![Summarizes six studies which reported Co-concentrations in well and poorly functioning implants [@pone.0070359-Williams1], [@pone.0070359-Hart1], [@pone.0070359-Kwon2], [@pone.0070359-Matthies1], [@pone.0070359-Langton4].\
Cases with local metal-related adverse reactions (poorly functioning implants) had consistently higher metal ion concentrations than patients with well-functioning THA.](pone.0070359.g003){#pone-0070359-g003}

10.1371/journal.pone.0070359.t012

###### Documentation of local metal-related adverse reactions.

![](pone.0070359.t012){#pone-0070359-t012-12}

  Reference                                       local clinical reactions
  ---------------- ---------------------------------------------------------------------------------------
  Bolland 2011                          14 patients (7.6 %) with revision due to ARMD
  DeSmet 2008                               10 patients (38.5 %) with metallosis
  Kwon 2010                        10 patients (14.3 %) with pseudotumors diagnosed by MRI
  Kwon 2011                          7 patients (4 %) with pseudotumors diagnosed by MRI
  Langton 2010                           16 patients with ASR, revision due to ARMD
  Langton 2011a                     60 failures related to ARMD, incl. patients with ASR
  Langton 2011c            82 failures (31.9 %) related to ARMD, patients with ASR HRA and ASR THA
  Matthies 2011b    72 patients (68.6 %, incl. patients with ASR) with pseudotumors diagnosed by MARS-MRI
  Williams 2011                 15 patients (20 %) with pseudotumors diagnosed by ultrasound

ARMD  =  adverse reaction to metal debris.

ASR  =  Articular Surface Replacement, Firma DePuy.

MRI  =  Magnetic Resonance Imaging.

MARS-MRI  =  Metal Artifact Reduction Sequence-Magnetic Resonance Imaging.

Systemic clinical reactions {#s3i}
---------------------------

Five studies [@pone.0070359-Grbl2], [@pone.0070359-Marker1], [@pone.0070359-Corradi1], [@pone.0070359-Daniel1], [@pone.0070359-Yang1] examined possible associations between metal ion concentrations and nephrotoxicity. Daniel et al. [@pone.0070359-Daniel1] examined renal clearance and renal concentrating efficiency of cobalt. The renal efficiency, i.e. the ratio of urine cobalt concentration to plasma cobalt concentration, was 0.9 (IQR 0.7--1.6) for preoperative controls and 3.2 (IQR 1.7--5.1) in patients with MoM THA or HRA. No threshold was endorsed at which renal capacity is overextended. Corradi et al. [@pone.0070359-Corradi1] examined metal ion concentrations in whole blood and renal markers in patients with HRA and in healthy controls. The median Co-excretion in patients with HRA was 12.9 µg/24-h urine (range 6.1--71.5 µg). No elevated renal markers were found in comparison with controls. Gruebl et al. and Marker et al. [@pone.0070359-Grbl2], [@pone.0070359-Marker1] investigated serum metal ions, blood urea nitrogen, and serum creatinine in overlapping cohorts of patients with MoM THA. The median (range) serum creatinine value preoperatively and at 10 years follow-up was 0.88 mg/dL (0.63--1.21 mg/dL) and 0.86 mg/dL (0.55--1.51 mg/dL), respectively. Evidence for or against further systemic toxicity or carcinogenicity could not be revealed from the studies included.

Discussion {#s4}
==========

As highlighted in this comprehensive systematic review, there is substantial and consistent evidence that patients receiving hip replacement with a MoM-bearing are at increased risk for systemic accumulation of metallic products. In the 104 studies analyzed, median metal ion concentrations were persistently elevated after implantation of MoM-bearings in all investigated mediums (whole blood, serum, plasma, erythrocytes, urine), irrespective of patient characteristics and study characteristics.

Overall, metal ion concentrations in body fluids were assessed in 9.957 patients in the 11 RCTs and 93 epidemiological studies included in this review. Despite heterogeneity in the study designs, techniques and medium of metal ion assessment, investigators consistently observed elevated median/mean metal ion concentrations after MoM THA and HRA compared to baseline, i.e. before surgery. Metal-free hip replacements did not result in increased metal ion levels. Metal ion concentrations following MoP and MoC THA were much lower compared to MoM THA or HRA.

One important finding from this review is that stemmed large-head MoM-implants and HRA tended to result in higher Co-concentrations than small-head MoM-implants. In several studies very high serum cobalt concentrations above 50 µg/L were measured in patients who had received large-head MoM-implants or HRA.

These findings have significant clinical relevance, as increased metal ion concentrations translate into increased risk for the development of local adverse reactions such as ARMD. In many cases ARMD results in the indication for the revision of MoM-implants.[@pone.0070359-Langton3] One current issue of debate is the definition of a cutoff cobalt level, above which revision should be considered.

Hart et al. [@pone.0070359-vanderStraeten1], [@pone.0070359-Hart1], [@pone.0070359-EFORT1] recommend a serum cobalt threshold level of 4.97 µg/L based on ROC-curve analyses. However, no explicit advice is given on how to treat patients above this value. Recommendations of present literature currently state Co-concentrations in serum or plasma greater 2 up to 7 µg/L as a predictor for a subjectively adverse outcome and an increased risk of MoM-specific complications [@pone.0070359-vanderStraeten1], [@pone.0070359-Hart1], [@pone.0070359-EFORT1], [@pone.0070359-Malek1].

While MoM SH-THA (head diameter ≤32 mm) seem to show similar long-term survival rates as hip replacement with other bearings [@pone.0070359-Grbl2], [@pone.0070359-Delaunay1], [@pone.0070359-Eswaramoorthy1], [@pone.0070359-Streit1], [@pone.0070359-Zenz1], the implantation of stemmed LH-THA (head diameter ≥36 mm) is associated with significantly higher short-term revision rates in clinical studies as well as arthroplasty registries [@pone.0070359-AustralianOrthopaedic1], [@pone.0070359-AustralianOrthopaedic2], [@pone.0070359-NationalJoint1], [@pone.0070359-Vendittoli2], [@pone.0070359-Clarke1], [@pone.0070359-Beaule1], [@pone.0070359-Bolland1], [@pone.0070359-Lavigne1], [@pone.0070359-Smith1]. The elevated release of metal products in these stemmed LH-implants may be due to fretting corrosion at the head-taper-junction in addition to a metal particle release from bearing surfaces.

Beside local tissue damages, it is important to gain better understanding about the potential systemic adverse effects induced by metal ion accumulation, i.e. toxicity, carcinogenicity, teratogenicity. The degree to which increased metal ion concentrations after MoM THA translate into increased risk for systemic toxicity cannot be sufficiently answered based on the studies identified and analyzed in this review. Until now, epidemiological studies have not revealed clinically relevant toxic damages of the kidney, heart or nervous system after MoM THA [@pone.0070359-Clarke1], [@pone.0070359-Langton6]-[@pone.0070359-Moroni2]. Case reports, however, indicate the possibility of metal-induced cardiomyopathy [@pone.0070359-Machado1], [@pone.0070359-Oldenburg1]. An elevated risk of incident cancer following hip replacements with MoM bearing could not be identified yet [@pone.0070359-Mkel1], [@pone.0070359-Visuri1], [@pone.0070359-Visuri2], but studies may have been underpowered.

There is substantial evidence that occupational metal exposure is related to increased cancer risk. It has to be noted, however, that bioavailability of Cr(III) compounds is substantially lower than those of Cr(VI) compounds. Cr(VI) compounds are able to infiltrate into cells due to transmembrane motion and to operate genotoxic following reduction to Cr(III). Carbid metal workers exposed to Co are at increased risk for fatal lung cancer [@pone.0070359-Moulin1]; the „International Agency for Research on Cancer (IARC)" classified Co to be possibly carcinogenic. Persons being occupationally exposed to Co have higher Co urine concentrations when compared to the general population. It should be noted that specific attentiveness was laid on possibly elevated Cr(VI) in body fluids due to ascertained carcinogenicity of Cr(VI) compounds. Due to considerable differences in exposure routes, the effects of increased metal ion concentrations as a consequence of MoM hip replacement cannot be directly compared with the systemic effects of occupationally acquired (mainly inhaled) metals.

Strengths and weaknesses of this review {#s4a}
---------------------------------------

This systematic review was conducted in accordance with the PRISMA checklist [@pone.0070359-Moher1]. Systematic literature search and assessment of eligibility of studies identified was done independently by two reviewers. Study quality assessment was based on a priori defined criteria. Due to methodological limitations in most of the studies included and due to substantial qualitative differences in the study design, conduct, and reporting, quantitative meta-analysis was not indicated. However, as highlighted above, the qualitative results are consistent despite the heterogeneity of the studies included so that we consider the conclusions drawn to be robust and generalizable.

Implications for clinical practice and future research {#s4b}
------------------------------------------------------

After hip replacement with contemporary MoM bearings the release of metal ions is highest in stemmed implants with large heads followed by resurfacing devices and also -- but on a lower level -- small heads. As the deposition of metal products may not only lead to local but possibly also systemic adverse health outcomes, the conclusions of this review have high relevance not only for orthopaedic surgeons, but also for other medical disciplines.

Due to the risk of systemic accumulation of metal ions following implantation of hip replacements with MoM bearing, consideration on risks and benefits should be done carefully and individually for every patient prior to surgery.

The authors support a „time out" of stemmed large-head MoM-THA and recommend a restricted indication for hip resurfacing arthroplasty to patients without risk factors such as small implant size, female gender, and renal insufficiency [@pone.0070359-Kwon1], [@pone.0070359-Smith1]. Patients with status post implantation of MoM should be followed by standardized monitoring. Especially examined ions, medium and analysis technique should be standardized to allow comparability of results and further analysis. Close interdisciplinary cooperation is necessary in case of potential systemic reactions due to increased metal ion concentrations.

An approach to this unresolved difficulty was one of the main objectives of an international and interdisciplinary expert conference, which took place in our institution. In April 2012, we hosted an international multi-disciplinary expert conference endorsed by the "European Federation of National Associations of Orthopaedics and Traumatology" (EFORT), "European Hip Society" (EHS), and the "German Osteoarthritis Society" in order to provide clinically-relevant advice on how to treat and monitor current and future patients with MoM THR. Beside orthopaedic surgeons being experienced with MoM hip endoprosthetics, epidemiologists, toxicologists, biomechanics, and pathologists as well as a patients representative and regulatory agency representative from 7 European countries and the US participated.

The statement resulting from this consensus initiative is published in detail on web sites of European [@pone.0070359-EFORT1] and German [@pone.0070359-Arbeitsgemeinschaft1], [@pone.0070359-DGOOC1] orthopaedic societies [@pone.0070359-Hannemann1]. Beside detailed recommendations on monitoring of MoM hip replacements and metal ion measurement the statement also summarizes prioritized questions for future research. One research issue that needs to be prioritized is the investigation of potential systemic risks due to accumulation of metal ions.
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